Welcome to our dedicated page for TuHURA Biosciences SEC filings (Ticker: HURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TuHURA Biosciences, Inc. (NASDAQ: HURA) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. TuHURA is a Phase 3 immuno-oncology company developing IFx-2.0, a lead innate immune agonist for advanced or metastatic Merkel cell carcinoma, the VISTA inhibiting monoclonal antibody TBS-2025 for NPM1-mutated relapsed/refractory acute myeloid leukemia, and Delta Opioid Receptor-based antibody drug conjugate programs aimed at overcoming resistance to cancer immunotherapy.
Through this page, users can review TuHURA’s current and historical filings, including Form 10-K annual reports, Form 10-Q quarterly reports, and Form 8-K current reports that disclose material events. Recent 8-K filings describe, among other items, the completion of the acquisition of Kineta, Inc., the reverse merger with Kintara Therapeutics, Inc., the initiation of the Phase 3 IFx-2.0 trial under a Special Protocol Assessment agreement with the FDA, the establishment of an at-the-market offering facility, a secured bridge loan agreement, and the effectiveness of a shelf registration statement on Form S-3.
Investors can also use this page to locate registration statements such as Form S-1 and Form S-3 related to public and resale offerings of TuHURA’s common stock, including PIPE financings and warrant exercises. Where applicable, pro forma financial information filed as exhibits to 8-Ks provides combined financial data reflecting TuHURA’s merger transactions. Insider ownership changes and executive equity activity, when reported on Form 4 and related forms, can be monitored alongside these core filings.
Stock Titan enhances this raw filing data with AI-powered summaries that highlight key points from lengthy documents, helping users understand how TuHURA’s clinical development plans, risk factor updates, financing arrangements, and merger-related disclosures appear in its official SEC reports. Real-time updates from EDGAR ensure that new TuHURA filings, including 10-Ks, 10-Qs, 8-Ks, registration statements, and ownership reports, are quickly available for review and comparison.
TuHURA Biosciences, Inc. received a notice from Nasdaq that its common stock no longer meets the minimum bid price requirement because the consolidated closing bid has been below $1.00 per share for 35 consecutive business days as of January 28, 2026. The stock is not being immediately delisted, and the company has a 180-day grace period, until July 28, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for at least ten consecutive business days. If it still fails to comply, TuHURA may be eligible for a second 180-day period, potentially including measures such as a reverse stock split, and could also request a hearing to delay any suspension or delisting. The company states that the notice does not affect its business, operations, or SEC reporting, but it cautions that there is no assurance it will regain or maintain Nasdaq listing compliance.
TuHURA Biosciences, Inc. reported an insider equity award for its Chief Financial Officer, Dan Dearborn. On January 6, 2026, he was granted 273,696 options (right to buy common stock) with an exercise price of $0.73 per share, expiring on January 6, 2036. The options were acquired at no cost and are held directly. According to the footnote, this is a supplemental option grant to an option grant previously made in December 2025, and one-third of the stock options become exercisable on the first, second, and third anniversary of January 6, 2025.
TuHURA Biosciences, Inc. reported an insider equity award for its Chief Executive Officer and director, James A. Bianco. On January 6, 2026, he received an award of 610,332 stock options (options right to buy common stock) with an exercise price of $0.73 per share and an expiration date of January 6, 2036. The options were granted at no cost as a supplemental option grant to one previously made in December 2025.
According to the disclosure, one-third of these stock options become exercisable on the first, second, and third anniversary of January 6, 2025, creating a three-year vesting schedule. Following this grant, Bianco beneficially owns 610,332 derivative securities directly.
TuHURA Biosciences, Inc. (HURA) reported that its Chief Financial Officer, Dan Dearborn, received stock options to purchase 1,531,367 shares of common stock at an exercise price of $1.02 per share on 12/12/2025.
The options are held directly, expire on 12/12/2035, and cover 1,531,367 underlying shares, which is also the number of derivative securities beneficially owned after the transaction. One-third of the stock options becomes exercisable on each of the first, second, and third anniversaries of 12/12/2025, creating a three-year vesting schedule.
TuHURA Biosciences, Inc. insider James Bianco, the company’s chief executive officer and a director, reported acquiring stock options on 12/12/2025. The options give him the right to buy up to 3,414,891 shares of TuHURA common stock at an exercise price of $1.02 per share and are scheduled to expire on 12/12/2035.
According to the filing, these options were acquired in a single transaction coded "A" and had a reported price of $0 for the derivative security itself. A footnote explains that one-third of the options become exercisable on each of the first, second, and third anniversaries of December 12, 2025. Following this transaction, Bianco beneficially owns 3,414,891 stock options directly.
TuHURA Biosciences, Inc. reports that a previously registered offer and sale of up to 9,321,545 shares of its common stock will now be covered by its effective Form S-3 shelf registration statement. These shares consist of 4,570,629 shares of common stock sold in a June 2, 2025 private placement and 4,750,916 shares issuable upon exercise of related warrants, all originally registered on a Form S-1 resale registration statement.
The Form S-3 shelf registration statement (File No. 333-291239), initially filed on November 3, 2025, became effective on November 22, 2025 under Section 8(a) of the Securities Act. Under Section 415(a)(6), the earlier Form S-1 resale registration is deemed terminated, and the same selling securityholders may now offer the same shares from time to time under the new shelf registration.
TuHURA Biosciences, Inc. has filed a mixed shelf prospectus allowing it to offer and sell up to $250,000,000 of debt, common stock, preferred stock, warrants, subscription rights, units and purchase contracts over time. The prospectus also registers 9,321,545 shares of common stock for resale by existing investors, including 4,570,629 outstanding shares and 4,750,916 shares issuable upon warrant exercise; TuHURA will not receive proceeds from these stockholder resales. The company is a clinical-stage immuno-oncology business, led by its IFx platform and a Phase 3 trial of IFx-2.0 in Merkel cell carcinoma, and plans to investigate TBS-2025 in a Phase 2 trial in AML. TuHURA states that net proceeds from its own future offerings will be used for working capital, Kineta merger-related costs and to advance its IFx-2.0 and TBS-2025 programs.
TuHURA Biosciences, Inc. reported that it has prepared updated unaudited pro forma financial information reflecting its recent merger activity. The company completed a two-step merger with Kineta, Inc. on June 30, 2025, following an Agreement and Plan of Merger initially signed in December 2024 and amended in May 2025. In addition, TuHURA previously closed a reverse merger with Kintara Therapeutics, Inc. on October 18, 2024.
TuHURA is now providing an unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2025 and for the year ended December 31, 2024, as if both the Kineta transaction and the Kintara reverse merger had occurred on January 1, 2024. These pro forma statements, furnished as Exhibit 99.1, are meant to help investors understand how the combined business would have looked historically after these mergers.
TuHURA Biosciences (HURA) reported a larger quarterly loss and flagged liquidity risk. For Q3 2025, net loss was $7.1 million as research and development reached $5.0 million and general and administrative expenses were $1.8 million. Cash and cash equivalents were $2.7 million at September 30, 2025.
The company closed the Kineta acquisition on June 30, recording $13.6 million of goodwill and $8.3 million of in‑process R&D tied to TBS‑2025. In June, TuHURA raised approximately $12.6 million via a private placement of 4,759,309 shares and the same number of warrants at a $3.3125 exercise price; $0.5 million of the deferred tranche remained as of quarter‑end. A resale registration for those securities became effective on September 26.
Management disclosed substantial doubt about continuing as a going concern. Operating cash outflow was $22.1 million for the first nine months of 2025. Subsequent events include a secured bridge loan of up to $3.0 million at 3% (initial $1.5 million funded) and filing of a $50 million at‑the‑market program that awaits SEC effectiveness. Shares outstanding were 51,258,085 as of November 12, 2025.
TuHURA Biosciences furnished an 8-K announcing that it issued a press release with financial results for the three months ended September 30, 2025, and a corporate update. The press release is attached as Exhibit 99.1 and is incorporated by reference. The information under Item 2.02, including Exhibit 99.1, is being furnished and not deemed filed under the Securities Exchange Act of 1934.
TuHURA’s common stock trades on The Nasdaq Capital Market under the symbol HURA.
FAQ
What is the current stock price of TuHURA Biosciences (HURA)?
What is the market cap of TuHURA Biosciences (HURA)?
